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OBJECTIVE — Toexplorepatients’andhealthprofessionals’experiencesofinitiatinginsulin
as part of the Treating To Target in Type 2 Diabetes (4-T) randomized controlled trial.
RESEARCH DESIGN AND METHODS — Interviews were conducted with 45 trial
participants and 21 health professionals and thematically analyzed.
RESULTS — Patients were generally psychologically insulin receptive when approached to
participate in the 4-T trial. Their receptiveness arose largely from their personal experiences
observingintensifyingpriortreatmentsanddeterioratingbloodglucosecontrolovertime,which
led them to engage with and accept the idea that their diabetes was progressive. Health profes-
sionals also fostered receptiveness by drawing on their clinical experience to manage patients’
anxieties about initiating insulin.
CONCLUSIONS — Previous studies may have overemphasized the problem of psycholog-
ical insulin resistance and overlooked factors and treatment experiences that may promote
insulin receptiveness among type 2 patients.
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A
ccording to the literature, psycho-
logical insulin resistance can arise
from patients’ feelings of personal
failure to effectively self-manage their di-
abetes, anxieties about injecting, and
from health professionals’ clinical inertia
and lack of knowledge and experience
with insulin therapy (1–6). Psychological
insulin resistance can result in delays in
treatment initiation. There is, however,
limitedqualitativeresearchdrawingupon
patients’ and health professionals’ experi-
encesofinitiatinginsulintherapy.There-
ported ﬁndings are from a qualitative
study involving patients and health pro-
fessionals who, through their participa-
tion in the Treating To Target in Type 2
Diabetes(4-T)trial,initiatedinsulinusing
randomized analog insulin regimens
(basal, prandial, and biphasic) (7,8).
RESEARCH DESIGN AND
METHODS— The study included 11
ofthe584-Tcenters,whichwereselected
to reﬂect diversity in center size and geo-
graphical location. Patients and health
professionals were recruited using an
opt-in procedure. Patients were purpo-
sively selected so that the sample com-
prised equal numbers from across the
trial’s three treatment arms; was broadly
representative of the wider trial popula-
tion in terms of age, sex, and glycemic
control (Table 1); and included trial par-
ticipants with high and low ﬁnal A1C re-
sults (range, 5.3–9.9%). At least one
health professional from each center was
interviewed (nine physicians and twelve
nurses).
The interviews—which explored (in-
depth) participants’ understandings and
experiences of insulin initiation—were
informed by topic guides and allowed
participants to raise issues that they per-
ceived as salient. The interviews were
conducted between October 2008 and
July2009,lastedbetween40minand2h,
andweredigitallyrecordedandfullytran-
scribed. Data collection and analysis took
place concurrently. Findings and themes
identiﬁedinearlyinterviewsinformedar-
eas explored in later ones, in line with an
inductive, thematic approach (9). Data
were coded using methods of constant
comparison (9). A qualitative data-
indexing package (QSR NVivo 2) facili-
tated data coding and retrieval.
RESULTS— We had anticipated that
negative beliefs about insulin and resis-
tance to start insulin therapy would fea-
ture widely in patients’ accounts.
However, the vast majority was what we
term “psychologically insulin receptive”
when approached to participate in 4-T.
The key factors that fostered receptive-
ness are explored below.
Engaging with disease progression
For the majority of patients, the ﬁrst time
they had been recommended insulin had
been immediately prior to trial enroll-
ment. Patients frequently claimed to have
been upset, disappointed, or shocked
when advised that they needed insulin.
However, accounts of having personally
failed to self-manage their diabetes—or
resistance to initiating insulin—were ex-
tremely rare. Most patients described ac-
ceptingthattheyrequiredinsulinbecause
they realized their diabetes had pro-
gressed. This realization arose from ob-
serving their oral glucose lowering
medications increase over time, often to
maximum doses, and their glucose con-
trol deteriorate despite following their
treatment regimens. Experiences of un-
dertaking self-monitoring of blood glu-
cose (SMBG) or comparing successive
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gagementswiththeirdiseaseprogression.
Armed with these experiences, some re-
ported actually approaching their physi-
cian and requesting insulin.
“The doctor said anything under ten
(mmol/l)wasacceptable.Istartedtestingmy
bloodglucoselevelsandthatwasreallywhen
Ibegantorealizethattabletsweren’thelping
me.SoIwenttothedoctorandsaid,‘Iwantto
go on insulin.’” – Patient 20
Managing anxieties about insulin
therapy
Although psychologically receptive to-
ward initiating insulin therapy, most pa-
tients described being anxious about the
prospect of injecting. In most cases, these
anxieties appeared to have been managed
effectively by health professionals who
were usually highly experienced in initi-
atinginsulin.Patientsfrequentlyreported
beingpleasantlysurprisedupondiscover-
ingthattheywouldbeusinginsulinpens.
Insulin pens were seen as being more dis-
crete, less painful to use, and easier to
transport than the syringes patients had
anticipated using. Nurses described how
encouraging engagement with SMBG re-
sults, prescribing low starting doses of in-
sulin, and supervising initial injections
were some of their tried-and-tested tech-
niques for easing patients’ transitions
onto insulin. The structured program of
face-to-face and telephone support deliv-
ered as part of 4-T provided health pro-
fessionals with opportunities to employ
thesepracticesinordertocoaxmoreanx-
ious trial participants through the initia-
tion period.
“I had one patient on the 4-T study who
wasnotgoingtogooninsulinbecausehewas
terriﬁedofneedles,andthenIbroughthimin
here and I said, ‘Well, let me show you,’ you
know, and I got him to do an injection and he
said, ‘I did not feel anything,’ and then he
came into the study.” – Health Care Pro-
vider 1
CONCLUSIONS— Previous studies
have placed strong emphasis on the need
to overcome patients’ psychological insu-
lin resistance, yet they have also shown
that the majority of their study partici-
pants were, in fact, willing to initiate in-
sulin. For example, in one key paper (2)
focusing on psychological resistance to
insulin, 71.7% of noninsulin-treated type
2 patients were, to varying degrees, will-
ing to initiate insulin therapy with almost
one-fourth being “very willing.” Also,
73%ofpatientsrandomizedtotheinsulin
armoftheUKProspectiveDiabetesStudy
(UKPDS) accepted treatment (10). In line
with these ﬁndings, our study suggests
that receptiveness, rather than resistance,
may be a more common experience
among patients with type 2 diabetes. It is
possible,therefore,thatpreviousresearch
has overemphasized the difﬁculties asso-
ciated with resistance to the detriment of
exploring factors that can promote
receptiveness.
Encouraging SMBG at the point
where insulin is being recommended, ed-
ucating patients about acceptable ranges
for their readings, and offering a discus-
sion of A1C results in diabetes review vis-
its may help promote psychological
insulin receptiveness. Providing patients
with insulin pens and a structured pro-
gram of support during initiation may
also help patients to overcome their anx-
ieties about insulin.
Limitations of the study
ThestudywaslimitedtotheU.K.,andthe
vast majority of those interviewed were
white and British. By virtue of having
agreed to participate in 4-T, patients may
have held more positive beliefs about in-
sulin than those in nontrial settings.
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